Fibromyalgia News

The word “gaslighting” has taken on a life of its own in recent years, being used in the context of interpersonal relationships, political discourse and online chatter alike.

ORLANDO — Medical cannabis is growing in acceptance and has benefits for managing pain in patients with rheumatic diseases, but more research is required, a presenter said at the 2022 Rheumatology Nurses Society Conference.

Myositis Awareness Month is focused on raising awareness and amplifying voices for patients with diseases falling under the myositis umbrella.

The FDA has granted De Novo authorization for NeuroMetrix to market its Quell neuromodulation device as an aid for reducing fibromyalgia symptoms in adults with high pain sensitivity, according to a company press release.

More than 40% of patients with long COVID experience “fibromyalgia-like,” multisite pain, according to data released by Tonix Pharmaceuticals.

The COVID-19 pandemic has wrecked “significant negative impacts” on pain, function and treatment accessibility for individuals with chronic musculoskeletal pain, according to a speaker at the 2022 OARSI World Congress.

A sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride failed to achieve statistical significance in reducing fibromyalgia pain vs. placebo in a phase 3 trial, according to a press release.

Fatigue is not a new problem to rheumatologists, as we recognize it as one of the most common and difficult patient complaints that confronts us.

Adding duloxetine to usual care fails to result in any “clinically relevant effect” in patients with chronic hip or knee osteoarthritis pain, compared with usual care alone, according to data published in Arthritis & Rheumatology.

The COVID-19 pandemic brought with it a significant decrease in autoimmunity laboratory testing, first rheumatology visits and diagnoses from 2019 to 2020, according to Italian data published in The Journal of Rheumatology.